key: cord-0842418-s80u8ufn
authors: Fu, Yu; Zhu, Rui; Bai, Tao; Han, Ping; He, Qin; Jing, Mengjia; Xiong, Xiaofeng; Zhao, Xi; Quan, Runze; Chen, Chaoyue; Zhang, Ying; Tao, Meihui; Yi, Jianhua; Tian, Dean; Yan, Wei
title: Clinical Features of COVID‐19‐Infected Patients With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
date: 2020-06-30
journal: Hepatology
DOI: 10.1002/hep.31446
sha: 817e5187cdd7411a9e9f2f7ff11483ec0f4d16ac
doc_id: 842418
cord_uid: s80u8ufn

In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) emerged in Wuhan, China. Although it has been reported that some COVID‐19 patients showed elevated liver biochemistries, there are few studies regarding clinical features and prognosis of these patients. In this multicenter, retrospective study, we collected data on laboratory‐confirmed COVID‐19 patients from three hospitals in Wuhan, China, who died or were discharged between February 1, 2020, and February 20, 2020. The data on demographics, comorbidities, clinical symptoms, laboratory examinations on admission, complications, treatment, and outcome were collected. A total of 482 patients were enrolled in this study. Of those, 142 (29.5%) patients showed abnormal liver biochemistries on admission, and patients with elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) accounted for 67.6%, 69.0%, and 16.2%, respectively. Those with abnormal liver biochemistries showed higher percentages of severe cases and comorbidities and were more likely to have dyspnea, chest distress or pain, and increased hemoglobin (Hb) on admission. Higher rates of complications and mortality and worse recovery when discharged were observed in patients with abnormal AST or TBIL. The multivariable regression analysis showed that chest distress or pain (odds ratio [OR], 1.765; P = 0.018), dyspnea (OR, 2.495; P = 0.001), elevated C‐reactive protein [CRP] level (OR, 1.007; P = 0.008), elevated white blood count (WBC) (OR, 1.139; P = 0.013), and elevated Hb concentration (OR, 1.024; P = 0.001) were independent factors associated with elevated liver biochemistries in COVID‐19 patients. Conclusion: Elevated liver biochemistries were common in COVID‐19 patients. Patients with hypoxia or severe inflammation are more likely to experience increased liver biochemistries on admission. Those with abnormal AST or TBIL on admission are more likely to suffer from severe complications and death.

than in the normal liver biochemistries group (Table 3 .1). In the abnormal liver biochemistries group, there were more patients who had received corticosteroid therapy (7.7%; P = 0.010) before admission, whereas the proportion of patients who had undergone antiviral therapy (55.6%; P = 0.021) was relatively smaller (Table 1) .

After admission, the proportion of patients who had received corticosteroid therapy was also higher in the abnormal liver biochemistries group (47.2% vs. 32.9%; P = 0.003) ( Table 1) .

Compared with normal liver biochemistries, patients with abnormal liver biochemistries had poor prognosis with a significantly higher proportion of death (29.6% vs. 6.5%; P < 0.001), especially in the AST elevation group (33.7% vs. 8.1%; P < 0.001) and TBIL elevation group (60.9% vs. 10.9%; P < 0.001) ( Table 3 .1). Among patients with abnormal liver biochemistries, the percentages of patients who had achieved chest computed tomography (CT) improvement (57.7% vs. 72.9%; P = 0.001), normal CRP (28.9% vs. 42.9%; P = 0.004), and normal lymphocyte count (59.9% vs. 74.4%; P = 0.001) were lower than in the normal group when discharged (Table 1) .

Compared with the normal liver biochemistries group, patients with abnormal liver biochemistries had higher levels of CRP, leukocytes, creatinine, LDH, D-dimer, hemoglobin (Hb), high-sensitivity cardiac troponin I (hs-cTnI), and globulin and lower levels of lymphocytes, eosinophils, and albumin ( Table 2 ). The Hb of the abnormal liver biochemistries group (median, 132.5 g/L; IQR, 122.0-143.0) was higher than in the normal group (median, 127.0 g/L; IQR, 117.0-136.0) (P < 0.001), and the differences were statistically significant when grouped by ALT elevation (P = 0.001), AST elevation (P = 0.001), or TBIL elevation (P = 0.006). The levels of CRP and leukocytes in the liver biochemistries elevation groups were higher than in the normal groups (P < 0.001). The absolute values of lymphocytes in patients with elevated AST (P < 0.001) and TBIL (P = 0.003) were lower, and the TBIL elevation group had the minimum lymphocyte count of 0.7 × 10 9 /L (IQR, 0.4-1.1; P = 0.003) ( Table 3 .2). The levels of hs-cTnI were significantly higher in patients with elevated AST (10.7 vs. 3.6 pg/mL; P < 0.001) or TBIL (15.0 vs. 4.0 pg/mL; P = 0.002) than those with normal levels (Table 3. 2).

This article is protected by copyright. All rights reserved

Multivariate logistic regression was performed to analyze the factors associated with elevated liver biochemistries (Table 4 ). It was found that chest distress or pain (OR, 1.765; 95% CI, 1.104-2.820; P = 0.018) , dyspnea (OR, 2.495; 95% CI, 1.434-4.341; P = 0.001), elevated CRP (OR, 1.007; 95% CI, 1.002-1.012; P = 0.008), increased white blood count (WBC) (OR, 1.139; 95% CI, 1.028-1.263; P = 0.013), and increased Hb (OR, 1.024; 95% CI, 1.009-1.039; P = 0.001) were independent factors associated with elevated liver biochemistries.

In this multicenter, retrospective study, we found that elevated liver biochemistries were common in COVID-19

patients. Approximately one third of the subjects presented with elevated liver biochemistries on admission, which was similar with a previous report. (7) However, most of the patients just showed mild elevated liver biochemistries at the preliminary stage of infection, (8) which was consistent with what was found in our study that most patients only had slight elevation of ALT, AST, and TBIL on admission. The mechanism of abnormal liver biochemistries caused by SARS-COV-2 is still unclear. In our study, 19.9% of COVID-19 patients coexisted with chronic liver diseases (viral hepatitis and nonalcoholic fatty liver disease [NAFLD] ). Viral hepatitis co-comorbidity accounted for a higher proportion in patients with elevated liver biochemistries (P = 0.037). However, it is hard to say whether NAFLD co-comorbidity contributes to elevated liver biochemistries because we only had 5 NAFLD patients. Although patients with previous liver diseases were easier to develop with abnormal liver biochemistries, it was possible that they had abnormal biochemistries before infected by SARS-CoV-2. Of the patients, 4.8% presented with elevated TBIL, especially direct bilirubin (DBIL), and median DBIL/TBIL was 0.42 (0.34-0.48). As reported by a recent study, angiotensin-converting enzyme 2 (ACE2) was highly expressed in type II alveolar epithelial cells as well as in bile duct cells and had an important role in mediating SARS-CoV-2 infection. (9) These findings indicated that elevated TBIL may be associated with SARS-CoV-2-induced bile duct cells injury rather than direct hepatic cells injury caused by the virus. (10, 11) 

We demonstrated that CRP and leukocyte count were associated with abnormal liver biochemistries, which was consistent with a previous study. (12) CRP, an acute phase protein, is an indicator for active inflammation. An increased number of leukocytes is a response to bacterial infection. Both are important clinical inflammatory indicators. It has been reported that the levels of CRP and WBC were significantly higher in severe cases, (13) and abnormal liver biochemistries were more commonly seen in critical patients. (6) In a previous COVID-19 study, patients who had been admitted to the intensive care unit (ICU) had higher levels of ALT and AST relative to non-ICU patients, and the proportion of patients with elevated AST was also higher in ICU patients (62% vs. 37%). (14) According to another study, 39.4% of severe patients showed elevated AST, whereas 28.1% had elevated ALT, the proportion of which were both higher than nonsevere cases. (15) Thus, patients with severe disease were more likely to have elevated liver biochemistries, which may be related to cytokine storm. (6) Cytokine storm is an overactive inflammatory response caused by pathogens, leading to a persistent activation of lymphocytes and macrophages that can secrete an abundance of inflammatory cytokines, followed by ARDS and multiorgan failure. Previous studies have shown that cytokine storm was associated with poor outcomes in SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infection. (16, 17) As reported, inflammatory cytokines reached the peak a few days after hospitalization, indicating that some cytokines might be involved in early stage of abnormal liver biochemistries. (18) It was also demonstrated in a study that more than half of the COVID-19 patients had elevated liver enzymes, which may be associated with drug effects or overreaction of the immune system (19) In our study, 20 cases received glucocorticoids treatment before admission, including 17 severe patients. Based on the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia, glucocorticoids can be used in severe cases if necessary. The higher proportion of glucocorticoid therapy in patients with elevated liver biochemistries was possibly owing to the disease severity. Among the patients in this study, 63.5% received antiviral therapies before admission. Although more patients received antiviral treatments before admission in the normal liver biochemistries group, a report has demonstrated that the percentage of patients receiving lopinavir or ritonavir treatment after admission was markedly higher in patients with liver injury. (8) Accordingly,

prospective studies are needed to investigate the exact association between various antiviral agents and liver function. In addition, in a previous study, the liver biopsy specimens showed moderate microvesicular steatosis and mild lobular and portal necrosis, which could be related to either SARS-CoV-2 infection or drug-induced liver injury. (20) Concrete evidence is still needed to confirm the cause of abnormal liver biochemistries.

In our study, increased Hb, chest distress or pain, and dyspnea were found to be associated with abnormal liver biochemistries. Hb is a functional protein in red blood cells that can deliver oxygen from the lungs to the far reaches of the body, and increased Hb level is an indicator of chronic hypoxia. Chest distress and dyspnea indicate that oxygenation of the lungs may be significantly damaged. Hypoxia can cause liver damage through a decrease in membrane potential, reducing the level of adenosine triphosphate (ATP), damaging sodium pump activity, and increasing membrane permeability. (21) Liver congestion or ischemia can also cause secondary liver function damage in clinic. These results illustrated that hypoxia probably was a cause of abnormal liver biochemistries in COVID-19 patients.

In patients with elevated AST or TBIL, the proportions of severe and deceased cases and patients with ARDS and acute cardiac injury were higher compared with those in ALT-elevated patients, whereas the lymphocyte count was relatively lower. Our results showed that hs-cTnI was much higher in patients with elevated AST or TBIL, indicating that those patients may have cardiac injury. A previous study found that 7.2% of COVID-19 patients had elevated hs-cTnI. (22) Another study showed that hs-cTnI was elevated in the early stage of COVID-19 and sharply increased with the deterioration of the disease. (5) Elevation of hs-cTnI was more common in severe cases, and more than half of the deceased patients showed elevated hs-cTnI during hospitalization. Several studies have demonstrated that cardiac injury was associated with poor prognosis. (6, 15, 23) Thus, our results suggested that elevated AST and TBIL may be an indicator for cardiac injury and were associated with poor prognosis. In addition, as shown in the results, patients with elevated AST or TBIL had worse chest CT images and lower rates for normalization of CRP and lymphocyte count. Lymphocyte count is an important predictor for disease severity, prognosis, and therapeutic response. (14, 24) Therefore, patients with elevated AST or TBIL were more severe and had worse prognosis or recovery conditions, reminding us to pay Accepted Article close attention to these patients.

A previous study has demonstrated that LDH is the independent risk factor for poor outcomes (transfer to the ICU or in-hospital death) in SARS patients. (25) Owing to the poor specificity, LDH cannot represent the specific indicator for liver injury. (26) In our study, LDH level was higher in patients with elevated liver biochemistries.

Whether a combination of LDH, AST, and TBIL can more accurately predict the outcomes of COVID-19 patients needs further investigation.

This study has some limitations. First, it was a retrospective study, and some cases had incomplete medical history, such as the detailed treatment before hospitalization. Liver function of those patients with coexisting chronic liver diseases before infection cannot be evaluated. Second, death cases may affect the evaluation of some indices, such as the length of hospital stay, and asymptomatic or mild patients were isolated at home, so we were unable to enroll these patients. Third, direct evidence of abnormal liver biochemistries caused by SARS-COV-2 is still uncovered, and the underlying mechanism needs to be further studied.

In conclusion, our study demonstrated that although abnormal liver biochemistries were common in COVID-19 patients, most of them just showed mild elevation, which may result from chronic hypoxia and excessive inflammation. Patients with elevated AST or TBIL on admission may have cardiac injury simultaneously and need more attention because they had worse prognosis. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved Chronic kidney disease 6 (1.2%) 6 (1.6%) 0 (0%) 0.475 6 (1.6%) 0 (0%) 0.462 6 (1.3%) 0 (0%) 1.000 

This article is protected by copyright. All rights reserved 

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

World Health Organization. Coronavirus disease (COVID-19) situation report

Gender differences in patients with COVID-19: focus on severity and mortality

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical features of COVID-19-related liver functional abnormality

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection

Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

COVID-19 with different severity: a multi-center study of clinical features

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis

Risk factors related to hepatic injury in patients with corona virus disease 2019

How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Effect of anoxia and ATP depletion on the membrane potential and permeability of dog liver

Accepted Article This article is protected by copyright. All rights reserved

COVID-19 and cardiovascular disease

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

A major outbreak of severe acute respiratory syndrome in Hong Kong

Diagnostic value for acute myocardial infarction of creatine kinase and lactate dehydrogenase isoenzymes compared with total enzymes. Creatine kinase isoenzyme specificity for myocardial damage

Author names in bold designate shared co-first authorship

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; hs-cTnI, high-sensitivity cardiac troponin I; NA

Data are n/N (%) and median (IQR)

We thank Wei Yan for the conception and design of the study, the integrity of the data, and the accuracy of the data analysis; Yu Fu for designing the study and revising the manuscript; Ping Han, Rui Zhu, 

This article is protected by copyright. All rights reserved Zhao, Meihui Tao, Mengjia Jing, and Xiaofeng Xiong for drafting the manuscript; and all authors for contributing to data acquisition or interpretation and reviewing and approving the final manuscript. We also thank all of the medical workers for participating in the diagnosis and treatment of patients in Wuhan as well as all the patients involved in this study.

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved Accepted Article